USD 4.62
(0.87%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 10.52 Million USD | -22.13% |
2022 | 13.15 Million USD | 14.43% |
2021 | 11.49 Million USD | -0.03% |
2020 | 11.5 Million USD | 6.07% |
2019 | 10.84 Million USD | 24.1% |
2018 | 8.73 Million USD | 81.85% |
2017 | 4.8 Million USD | 131.96% |
2016 | 2.07 Million USD | -10.42% |
2015 | 2.31 Million USD | 26.61% |
2014 | 1.82 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 2.18 Million USD | -18.13% |
2024 Q1 | 2.72 Million USD | 95.12% |
2023 FY | 10.24 Million USD | -22.13% |
2023 Q1 | 2.93 Million USD | -11.29% |
2023 Q4 | 1.39 Million USD | -55.37% |
2023 Q3 | 3.12 Million USD | 4.49% |
2023 Q2 | 2.99 Million USD | 1.88% |
2022 Q2 | 3.57 Million USD | 25.09% |
2022 Q3 | 3.41 Million USD | -4.33% |
2022 FY | 13.15 Million USD | 14.43% |
2022 Q1 | 2.85 Million USD | -7.04% |
2022 Q4 | 3.31 Million USD | -3.04% |
2021 Q2 | 3.2 Million USD | 24.24% |
2021 FY | 11.49 Million USD | -0.03% |
2021 Q1 | 2.57 Million USD | 14.26% |
2021 Q4 | 3.07 Million USD | 15.88% |
2021 Q3 | 2.65 Million USD | -17.17% |
2020 Q4 | 2.25 Million USD | -30.75% |
2020 FY | 11.5 Million USD | 6.07% |
2020 Q3 | 3.25 Million USD | 12.6% |
2020 Q2 | 2.89 Million USD | -6.76% |
2020 Q1 | 3.1 Million USD | -0.95% |
2019 Q2 | 2.32 Million USD | -15.36% |
2019 Q1 | 2.74 Million USD | 37.17% |
2019 FY | 10.84 Million USD | 24.1% |
2019 Q4 | 3.13 Million USD | 18.56% |
2019 Q3 | 2.64 Million USD | 13.56% |
2018 Q4 | 2 Million USD | -3.15% |
2018 Q3 | 2.06 Million USD | 13.43% |
2018 Q2 | 1.82 Million USD | -35.89% |
2018 Q1 | 2.84 Million USD | 23.63% |
2018 FY | 8.73 Million USD | 81.85% |
2017 FY | 4.8 Million USD | 131.96% |
2017 Q1 | 360.69 Thousand USD | -39.54% |
2017 Q4 | 2.3 Million USD | 113.06% |
2017 Q2 | 1.06 Million USD | 195.04% |
2017 Q3 | 1.07 Million USD | 1.45% |
2016 Q2 | 494.31 Thousand USD | 32.36% |
2016 Q4 | 596.58 Thousand USD | -1.73% |
2016 Q1 | 373.45 Thousand USD | -36.05% |
2016 Q3 | 607.11 Thousand USD | 22.82% |
2016 FY | 2.07 Million USD | -10.42% |
2015 FY | 2.31 Million USD | 26.61% |
2015 Q4 | 583.99 Thousand USD | -14.31% |
2015 Q2 | 1.28 Million USD | 45.96% |
2015 Q3 | 681.52 Thousand USD | -46.8% |
2015 Q1 | 877.72 Thousand USD | 0.0% |
2014 FY | 1.82 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bionano Genomics, Inc. | 148.99 Million USD | 92.939% |
Prenetics Global Limited | 60.73 Million USD | 82.678% |
Star Equity Holdings, Inc. | 16.27 Million USD | 35.345% |
CareDx, Inc | 277.76 Million USD | 96.212% |
Exact Sciences Corporation | 2.06 Billion USD | 99.489% |
Exagen Inc. | 52.29 Million USD | 79.881% |
Inotiv, Inc. | 246.9 Million USD | 95.739% |
Guardant Health, Inc. | 901.62 Million USD | 98.833% |
Biodesix, Inc. | 77.41 Million USD | 86.411% |
BioNexus Gene Lab Corp. | 3.92 Million USD | -168.175% |
Precipio, Inc. | 13.63 Million USD | 22.857% |
iSpecimen Inc. | 16.27 Million USD | 35.365% |
Natera, Inc. | 938.98 Million USD | 98.88% |
Aspira Women's Health Inc. | 24.11 Million USD | 56.371% |
Standard BioTools Inc. | 113.48 Million USD | 90.73% |
23andMe Holding Co. | 420.73 Million USD | 97.499% |
Castle Biosciences, Inc. | 242.78 Million USD | 95.667% |
Personalis, Inc. | 128.14 Million USD | 91.79% |
Aclaris Therapeutics, Inc. | 110.52 Million USD | 90.481% |
Applied DNA Sciences, Inc. | 16.48 Million USD | 36.187% |
OpGen, Inc. | 30.65 Million USD | 65.684% |
T2 Biosystems, Inc. | 41.49 Million USD | 74.645% |
Myriad Genetics, Inc. | 600.1 Million USD | 98.247% |
ICON Public Limited Company | 755.64 Million USD | 98.608% |
NeoGenomics, Inc. | 341.25 Million USD | 96.917% |
Star Equity Holdings, Inc. | 16.27 Million USD | 35.345% |
IDEXX Laboratories, Inc. | 1.09 Billion USD | 99.037% |
RadNet, Inc. | 268.87 Million USD | 96.087% |
MDxHealth SA | 71.25 Million USD | 85.235% |
Psychemedics Corporation | 11.33 Million USD | 7.175% |
Illumina, Inc. | 3.81 Billion USD | 99.724% |
Check-Cap Ltd. | 19.28 Million USD | 45.452% |
Twist Bioscience Corporation | 354.18 Million USD | 97.03% |
DarioHealth Corp. | 62.17 Million USD | 83.078% |
Fulgent Genetics, Inc. | 171.9 Million USD | 93.88% |
Sera Prognostics, Inc. | 39.91 Million USD | 73.643% |
OPKO Health, Inc. | 574.68 Million USD | 98.169% |
Medpace Holdings, Inc. | 187.68 Million USD | 94.394% |
Neogen Corporation | 405.23 Million USD | 97.404% |
Intelligent Bio Solutions Inc. | 11.7 Million USD | 10.147% |
Prenetics Global Limited | 60.73 Million USD | 82.678% |
Mainz Biomed B.V. | 27.15 Million USD | 61.256% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -20.033% |
Trinity Biotech plc | 46.49 Million USD | 77.372% |
Neuronetics, Inc. | 82.25 Million USD | 87.21% |
Sotera Health Company | 300.46 Million USD | 96.499% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -20.033% |